Introduction {#s1}
============

In 1965, Monod, Wyman and Changeux postulated the model of allosteric modulation in proteins ([@bib45]). According to this model, proteins exist in two possible conformational states, the tensed (T) or relaxed state (R). The substrate typically has a high affinity for the T state. In multi-subunit proteins, all subunits undergo a concerted transition from the R to the T state upon substrate binding. The equilibrium can be shifted to the R or the T state through a ligand that binds at a site that is different from the substrate binding site, in other words an allosteric site.

Changeux subsequently devoted much of his scientific career to the study of allosteric proteins, with specific attention paid to the nicotinic acetylcholine receptor (nAChR). This protein is a ligand-gated ion channel (LGIC) and thus in effect has no substrate, but the principle of allosteric modulation is similar in that binding of acetylcholine (ACh) shifts the thermodynamic equilibrium from a closed channel state to an open channel state through binding to a site \~50 Å away from the channel gate. The nAChR is a member of a superfamily of pentameric LGICs (pLGICs), which play major roles in fast synaptic transmission in the central and peripheral nervous systems, and are the site of action of many therapeutic drugs.

Structures of these proteins have been elucidated over the last decade and several nAChR structures are now available for the heteromeric α4β2 and α3β4 nAChRs ([@bib46]; [@bib64]; [@bib17]), as well as other members of the pLGIC family, including the 5-HT~3~ serotonin receptor ([@bib21]; [@bib52]; [@bib3]), the glycine receptor ([@bib14]; [@bib26]), the GABA~A~ receptor ([@bib67]; [@bib51]; [@bib34]; [@bib39]; [@bib43]), the glutamate-gated chloride channel from *C. elegans* GluCl ([@bib22]; [@bib2]) and the prokaryote channels ELIC ([@bib23]) and GLIC ([@bib24]; [@bib6]). Historically, crucial structural insight into the class of nicotinic receptors was derived from cryo-electron microscopic structures of the nAChRs from the electric organ of *Torpedo* ([@bib44]; [@bib62]) and X-ray crystal structures of the acetylcholine binding protein (AChBP; found in certain snails and worms), which is homologous to the extracellular ligand binding domain (LBD) of nAChRs ([@bib7]).

The concept of allosteric modulation is now also more broadly applied to understand the mode of action of certain drugs, called allosteric modulators, which bind at a site that is different from the neurotransmitter binding site, but which can alter energy barriers between multiple conformational states ([@bib5]). For example in the case of pLGICs, positive allosteric modulators (PAMs) of the nAChR can facilitate a transition from a resting to an activated state, thus enhancing the agonist-evoked response. In contrast, negative allosteric modulators (NAMs) hinder such a transition, thus diminishing the agonist response. From a drug development perspective, PAMs or NAMs are highly attractive as they finely tune receptor activation without affecting the normal fluctuations of neurotransmitter release at the synapse. One of the most extensively described PAMs used in the clinic are the benzodiazepines, which act on GABA~A~ receptors and are widely prescribed as hypnotics, anxiolytics, anti-epileptics or muscle relaxants. Important insights into the molecular recognition of these modulators have been revealed by high-resolution structural data ([@bib67]; [@bib51]; [@bib34]; [@bib39]; [@bib43]).

With the availability of a growing amount of structural data for these receptors, a diverse array of modulatory molecules have been identified, many of which bind at distinct allosteric binding sites, including general anesthetics ([@bib47]; [@bib53]; [@bib59]), neurosteroids ([@bib41]; [@bib33]; [@bib11]), lipids ([@bib67]; [@bib34]), antiparasitics ([@bib22]; [@bib2]), and many others ([@bib48]). Detailed investigation of allosteric sites not only brings further knowledge about the receptor functionality but also uncovers novel drug target sites. However, our current understanding of this multi-site mechanism of allosteric modulation in pLGICs is still incomplete.

In this study, we used complementary structural and functional approaches to expand our understanding of the molecular mechanism of allosteric modulation in pLGICs. Using the prokaryote ELIC channel as a model, we explored the potential of nanobodies (single chain antibodies) as allosteric modulators. We discovered functionally active nanobodies, which act either as a PAM or NAM on ELIC, and determined co-crystal structures to elucidate the nanobody interactions with ELIC. One of the structures reveals an allosteric binding site located near the vestibule of the extracellular ligand-binding domain. Comparison of conservation and divergence in this site in different prokaryotic and eukaryotic receptors suggests a mechanism for achieving subtype-selective allosteric modulation across the receptor superfamily. Using cysteine-scanning mutagenesis and electrophysiological recordings, we show the vestibule site can also be targeted for modulation of the human 5-HT~3A~ receptor as a proof of principle relevant to other eukaryotic receptors.

Results and discussion {#s2}
======================

Identification of nanobodies active as allosteric modulators on ELIC {#s2-1}
--------------------------------------------------------------------

In this study, we took advantage of nanobodies, which are high-affinity single chain antibodies derived from llamas; they have been widely employed to facilitate structural studies ([@bib38]) and also hold potential as therapeutics against many possible targets. A first example, caplacizumab (Cabilivi), has recently reached the market ([@bib55]). Using the prokaryote ion channel ELIC as a model system, we investigated whether nanobodies could be selected with allosteric modulator activity on ligand-gated ion channels. We expressed ELIC channels in *Xenopus* oocytes and employed automated electrophysiological recordings to characterize a panel of more than 20 different ELIC nanobodies. While none of the nanobodies had any functional effect on ELIC when applied alone, we found that co-application with the agonist GABA evoked a response that broadly falls into three categories. One type of nanobody enhanced the agonist-evoked response, while a second type of nanobody diminished the agonist-evoked response, and the third type had little to no effect. From these classes, we selected several enhancers (PAMs) and inhibitors (NAMs) for a detailed electrophysiological characterization as potential allosteric modulators. In parallel, we conducted X-ray diffraction screening of ELIC plus nanobody co-crystals for structural elucidation. From this selection, we obtained a PAM-active nanobody (PAM-Nb) as well as another NAM-active nanobody (NAM-Nb) and determined their structures bound to ELIC by X-ray crystallography.

Co-application of the agonist GABA with a range of PAM-Nb concentrations demonstrates that PAM-Nb enhances the agonist response ([Figure 1a](#fig1){ref-type="fig"}) with a pEC~50~-value of 5.37 ± 0.03 (EC~50~: 4.2 μM) and I~max~ = 257 ± 14% (mean values ± SEM, n = 8). In contrast, co-application of a range of NAM-Nb concentrations demonstrates that NAM-Nb decreases the agonist response ([Figure 1b](#fig1){ref-type="fig"}) with a pIC~50~-value of 6.89 ± 0.03 (IC~50~: 0.13 μM) and I~max~ = 34 ± 2% (n = 6). Unlike competitive antagonists, which fully inhibit the agonist response at saturating concentrations, the inhibition of NAM-Nb levels off at 70% of the response with GABA alone, consistent with the mode of action of certain NAMs. We further investigated the effects of PAM-Nb and NAM-Nb on the GABA concentration-activation curve and obtained results that support their effects as positive and negative allosteric modulators ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). These results demonstrate that functionally active nanobodies can be developed against the ligand-gated ion channel ELIC.

![Nanobodies active as allosteric modulators and structures bound to the ELIC channel.\
(**a, b**) Electrophysiological recordings of ELIC activated by the agonist GABA and in the presence of increasing concentrations of PAM-Nb (a, green) or NAM-Nb (b, red). The curve represents a fit to the Hill equation to the normalized current responses. Circles represent averaged data with standard errors. (**c,d**) X-ray crystal structures of ELIC bound by PAM-Nb (**c**) or NAM-Nb (**d**). The cartoon representation shows a top-down view onto the ELIC pentamer along the fivefold axis (blue). (**e,f**) Side views from **c,d**). The dashed lines indicate the presumed location of the membrane boundaries.\
Figure 1---source data 1.Electrophysiological recordings of ELIC with PAM-Nb and NAM-Nb.](elife-51511-fig1){#fig1}

Crystal structures of ELIC in complex with a PAM- or NAM-type nanobody {#s2-2}
----------------------------------------------------------------------

To gain insight into the structural recognition of positive (PAM-Nb) or negative (NAM-Nb) allosteric modulators, we solved X-ray crystal structures of ELIC in complex with the PAM-Nb or NAM-Nb, respectively ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). The structure of ELIC in complex with the PAM-Nb was determined at a resolution of 2.59 Å, and reveals five PAM-Nb molecules bound to a single pentameric ELIC channel ([Figure 1c,e](#fig1){ref-type="fig"}). Each PAM-Nb binds at an intrasubunit site in the ELIC extracellular ligand binding domain. When viewed from the top along the fivefold symmetry axis, the nanobodies extend outward and the structure resembles a five-bladed propeller ([Figure 1c](#fig1){ref-type="fig"}). The structure of ELIC in complex with NAM-Nb was determined at a resolution of 3.25 Å and is structurally distinct from the complex with PAM-Nb: instead of five Nb molecules bound to the ELIC pentamer, here a single NAM-Nb molecule is bound to the ELIC pentamer ([Figure 1d,f](#fig1){ref-type="fig"}). The NAM-Nb binds at the channel vestibule entrance and near to the N-terminal α-helix of a single ELIC subunit, and is oriented in such a manner that only a single nanobody molecule can bind at this interface, as the core of the nanobody sterically hinders access to the four other sites ([Figure 1d,f](#fig1){ref-type="fig"}).

A more detailed analysis of the interaction interface between both nanobodies and ELIC reveals remarkable features ([Figure 2](#fig2){ref-type="fig"}). The PAM-Nb binds to the extracellular ligand-binding domain and forms extensive interactions through the complementarity determining region CDR1 (residues S25-I33) of the nanobody ([Figure 2a](#fig2){ref-type="fig"}). The tip of the finger of this loop region wedges in between the ELIC β8- and β9-strand, forming a distinct anti-parallel β-sheet interaction with the β8-strand. The CDR1 loop region points toward an allosteric binding site previously identified in a chimera of the human α7 nAChR and the acetylcholine binding protein, α7-AChBP ([@bib35]) (see complex with fragment molecule CU2017, pdb code 5oui) ([Figure 2a](#fig2){ref-type="fig"}). In other words, the PAM-Nb binds to a site in ELIC that corresponds to a functionally important allosteric site in the human α7 nAChR, consistent with its function as an allosteric modulator.

![Detailed nanobody interaction sites in ELIC and channel pore analysis.\
(**a**) A detailed view of the interaction between PAM-Nb (green) and a single ELIC subunit (blue). The binding site for PAM-Nb overlaps with a known allosteric binding site, in a related pLGIC, for a small molecule fragment called CU2017, shown as spheres (carbon yellow, nitrogen blue) ([@bib12]; pdb code 5oui). (**b**) Detailed view of the interaction between NAM-Nb (red) and a single ELIC subunit (blue). The binding site for NAM-Nb involves a region which borders a known allosteric binding site for flurazepam in ELIC ([@bib58]; pdb code 2yoe). (**c,d**) Analysis of the ELIC channel pore radius for PAM-Nb, NAM-Nb bound structures and references structures.\
Figure 2---source data 1.Analysis of pore radius profiles.](elife-51511-fig2){#fig2}

The mode of interaction of the NAM-Nb with ELIC is distinct from the PAM-Nb ([Figure 2b](#fig2){ref-type="fig"}). The interaction interface is remarkable in that a unique α-helical region within the CDR3-region (P104-L110) forms the interface with ELIC. This α-helical region is positioned perpendicularly upon the α'1-helix in ELIC (N60-N69) and forms the outer rim of an allosteric binding site previously identified as the vestibule binding site ([@bib58]). This site is also the target for the benzodiazepine flurazepam, which acts as a positive allosteric modulator on ELIC ([@bib58]) ([Figure 2b](#fig2){ref-type="fig"} inset). This site is distinct from the high-affinity benzodiazepine site at the α/γ subunit interface ([@bib39]). Similar to the PAM-Nb, it is interesting to observe that the allosteric binding site of the NAM-Nb is adjacent to a previously identified binding site for a small molecule allosteric modulator. Remarkably, in each case, the nanobody has the opposite functional effect of the small molecule at the same site. The PAM-Nb acts as a positive modulator, whereas the CU2017 fragment acts as a negative modulator at the β8-β9 site. Conversely, the NAM-Nb acts as a negative modulator, whereas flurazepam acts as a positive modulator at the vestibule site. This result demonstrates that the same allosteric site can be targeted both by a PAM or NAM, and that its functional action likely depends on defined side chain interactions. This is in agreement with previous pharmacological studies, which have shown that a substitution as small as a methylation of an aromatic ring in a small molecule modulator can alter the functional profile from a PAM to a NAM of the α7 nAChR ([@bib18]). To further explore positive versus negative modulation, the atomic interactions of the PAM-Nb or NAM-Nb with ELIC are compared with those formed by the small molecules CU2017 or flurazepam, respectively (see [Figure 2---figure supplements 1](#fig2s1){ref-type="fig"}--[2](#fig2s2){ref-type="fig"}). The results from this analysis reveal some residues that are uniquely targeted in the PAM-Nb versus the CU2017 complex, which could be responsible for positive versus negative allosteric modulation ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Similarly in the NAM-Nb versus the flurazepam complex, adjacent subsets of residues in the vestibule site are targeted by the different molecules, again indicating that distinct residues within the same region play a role in negative versus positive allosteric modulation ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

The pores of both Nb complexes resemble previous structures of ELIC, with narrow constriction points at the 9ʹ, 16ʹ, and 20ʹ positions ([@bib23]), suggesting that the channels are in non-conducting conformations ([Figure 2c,d](#fig2){ref-type="fig"}). This closed state is structurally distinct from the putative desensitized state of the nAChR, whose primary gate lies at the cytoplasmic end at the −1ʹ position ([@bib46]; [@bib17]). Further analysis of the central channel axis of the NAM-Nb complex reveals a partial blockade of the extracellular vestibule entrance by the nanobody, resulting in a radius profile comparable to the 6' pore constriction ([Figure 2c,d](#fig2){ref-type="fig"}). This partial constriction of the ion permeation pathway could possibly explain why the NAM-Nb only partially inhibits GABA-induced currents. Alternatively, it is possible that in ELIC alternate pathways exist for ion entry through lateral fenestrations located at subunit interfaces, as seen in other members of the pLGIC family ([@bib67]; [@bib43]) ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Finally, NAM-Nb binding could restrict flexibility in the extracellular domain (ECD), thereby limiting a transition from a closed to a conductive conformation ([@bib54]).

Subtype-dependent vestibule site access in different prokaryote and eukaryote receptors {#s2-3}
---------------------------------------------------------------------------------------

To further investigate the possible conservation of the vestibule binding site in different prokaryote and eukaryote pLGICs, we performed a systematic analysis of the vestibule site architecture in all currently available pLGIC structures. The results from this analysis show that the outer rim of the vestibule site, which corresponds to residues N60-F95 in ELIC, can adopt one of three possible conformations ([Figure 3](#fig3){ref-type="fig"}).

![Distinct conformations of the vestibule site in pentameric ligand-gated ion channels.\
(**a--c**) Yellow ribbon representation of a single subunit ligand binding domain. Part of the vestibule site (shown in blue cartoon), called the Ω-loop, adopts three distinct conformations in different pLGICs: the Ω-in (red, (**a**), Ω-out (green, (**b**) and Ω-open conformation (magenta, (**c**). (**d-f**) Insets show a zoom of the Ω-loop in surface representation to illustrate occluded vestibule site access in the Ω-in and Ω-out conformations, compared to an accessible vestibule site in the Ω-open conformation. (**g--i**). Sequence alignment of the Ω-loop and neighboring residues in pLGICs for which structures have been elucidated.](elife-51511-fig3){#fig3}

In certain structures, we observe that the stretch of amino acids between the β4- and β5-strands resembles the shape of the Greek letter Ω, for example in the α4 nAChR subunit ([@bib46]; [@bib64]), and therefore this region is termed the Ω loop ([@bib25]). In [Figure 3a](#fig3){ref-type="fig"}, the outer rim of the vestibule site in the α4 nAChR is shown in blue (from the helix to the β5-strand) and the Ω loop in red. The tip of the Ω loop can either point into the vestibule as in the α4 nAChR subunit ([@bib46]; [@bib64]), which we call the Ω-in conformation ([Figure 3a](#fig3){ref-type="fig"}), or the tip of the Ω loop can point outward, which we call the Ω-out conformation, for example in the α1 GlyR subunit ([@bib14]) (outer rim shown in blue, Ω-out in green, [Figure 3b](#fig3){ref-type="fig"}). Importantly, in both of these conformations access to the vestibule site is occluded. In the Ω-in conformation, the tip of the Ω loop prevents access to the vestibule site of its own α4 nAChR-subunit ([Figure 3a,d](#fig3){ref-type="fig"}), whereas in the Ω-out conformation vestibule access is prevented by the tip of the Ω-out loop of its neighboring α1 GlyR (-) subunit ([Figure 3b,e](#fig3){ref-type="fig"}). In addition to the Ω-in and Ω-out conformations, we observe a third possible conformation in which the Ω loop is stretched, for example in the 5-HT~3A~R ([@bib21]) ([Figure 3c](#fig3){ref-type="fig"}) and ELIC, and creates an accessible vestibule site ([Figure 3f](#fig3){ref-type="fig"}). Consequently, we term this conformation the Ω-open conformation (Ω-open is shown in magenta, [Figure 3c,f](#fig3){ref-type="fig"}).

A systematic comparison of the Ω loop conformations demonstrates that the different pLGIC subfamilies group into defined categories (reference structures are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}). First, we observe that all currently known anionic receptor structures adopt the Ω-out conformation ([Figure 3h](#fig3){ref-type="fig"}). This implies that the vestibule access is occluded in all of these receptors, for example in the homomeric α1 GlyR ([@bib14]), α3 GlyR ([@bib26]), or GluCl ([@bib22]) as well as the heteropentameric α1βγ2 GABA~A~Rs ([@bib67]; [@bib51]; [@bib34]) and homopentameric β3 GABA~A~R ([@bib43]). The Ω-out loop sequence is strongly conserved in these receptors, with a His residue and Asn residue at either end of the Ω loop and a Thr at the tip (not conserved in GluCl). We also observe that in all these cases the Ω loop is preceded by a stretch of amino acids that forms an additional β-strand, which we call the β4'-strand, as it also follows the β4-strand. The β4'-strand contains a well conserved start Lys residue, which is present in GlyRs, GABA~A~Rs and GluCl. The sequence conservation in these two regions suggests an important functional role. In contrast with anionic receptors, we observe that certain cationic receptors can adopt either the Ω-in or Ω-open conformation. However, none of the cationic receptors adopt the Ω-out conformation. Only 5 nAChR subunits adopt the Ω-in conformation, namely the α2 nAChR ([@bib32]), α4 and β2 nAChR-subunits ([@bib46]; [@bib64]) and α3 and β4 nAChR-subunits ([@bib17]). This implies that the heteropentameric α4β2 and α3β4 nAChRs adopt an all-subunit-occluded vestibule site conformation. The stretch of amino acids that form the Ω-in conformation is also well conserved with a Gly-Val on either end and an aromatic residue (Phe/Tyr) at the tip, again suggesting an important functional role. In contrast, all other nAChR subunits ([@bib13]; [@bib68]), including the *Torpedo* nAChR ([@bib44]), as well as the 5-HT~3A~R ([@bib21]), snail AChBPs ([@bib7]; [@bib8]), prokaryote GLIC ([@bib6]; [@bib24]) and ELIC adopt the Ω-open conformation. The sequence of amino acids forming the Ω-open loop is less conserved, except for the position +two following the β4-sheet, which is a Asn in all receptors except 5-HT~3A~R. Important to note is that the Ω-open loop in the α9 nAChR ([@bib68]) is disordered in the apo state (pdb code 4d01), but not in the antagonist (MLA)-bound state (pdb code 4uxu). This raises the intriguing possibility that the Ω loop is conformationally flexible and could control access to the vestibule site. A comprehensive analysis of all pLGIC structures available to date further revealed that in certain structures the average B-factors per residue, which are used as an indicator of vibrational movement, are enhanced in the Ω-loop relative to other parts of the structure ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Some of the most striking examples are the Ω-in loop of the α3 subunit in the α3β4 nAChR (pdb code 6pv7, desensitized state) ([@bib17]), the Ω-out loop in POPC-bound GluCl (pdb code 4tnw, lipid-modulated state) ([@bib2]) and the Ω-open loop in GLIC T25'A (pdb code 4lmj, liganded closed state) ([@bib19]). These examples also represent possible intermediate or end states of the gating cycle, suggesting that the Ω-loop could show enhanced movement during the gating reaction. A functional role of the Ω-loop in gating of other pLGIC was demonstrated in earlier studies using a photochemical proteolysis approach of the Ω-loop in GABA~A~Rs ([@bib20]), incorporation of flexible glycine linkers in GABA~A~Rs ([@bib63]) and rate-equilibrium free energy relationship analysis of Ω-loop mutants of muscle nAChRs ([@bib9]).

Together, the results from this analysis demonstrate that different receptor subtypes adopt a different Ω loop conformation, with the Ω-open conformation creating an accessible vestibule site, whereas the Ω-in and Ω-out conformations occlude vestibule site access. Additionally, in heteropentameric GABA~A~ receptors the vestibule is occupied by N-linked glycan chains ([@bib67]; [@bib51]; [@bib34]), thus creating an additional level of restriction on vestibule site access in these and possibly other pLGICs. Our analyses provide new opportunities for drug design of allosteric molecules that have subtype-specific pharmacology (due to low sequence conservation compared to the orthosteric site), based on vestibule site access.

Cysteine-scanning mutagenesis in the vestibule site of the human 5-HT~3A~ receptor {#s2-4}
----------------------------------------------------------------------------------

Based on our observations that the vestibule site in ELIC is the target for positive allosteric modulators such as the benzodiazepine flurazepam ([@bib58]) as well as negative allosteric modulators such as the NAM-nanobody described in this study, we further investigated whether the mechanism of vestibule site modulation is functionally conserved in eukaryote receptors. We chose the 5-HT~3A~R as a prototype receptor since it has a clear Ω-open vestibule conformation and its structure ([@bib21]) as well as functional and pharmacological properties ([@bib37]) are well described. We then employed the substituted cysteine accessibility method (SCAM) ([@bib30]) to investigate the functional effects on channel gating before and after modification of cysteines in the 5-HT~3A~R vestibule site with the cysteine-reactive reagent MTSEA-biotin, which is approximately the size of a small molecule modulator such as flurazepam. We chose residues on the outer rim of the vestibule site, T112 (top) and F125 (bottom), respectively, as well as residues deeper into the vestibule site, N147, K149 and L151 on the β6-strand and Y86 on the β2-strand ([Figure 4b](#fig4){ref-type="fig"}). It is interesting to note that N147, K149 and L151 are located on the opposite side of the β-strand to the loop E residues (Q146 and Y148), while Y86 is on the opposite side of the β-strand to the loop D residues (W85 and R87); both of these regions are functionally important contributors to the neurotransmitter binding site ([@bib21]). Residue P111, which points away from the vestibule site, was included as a negative control.

![Allosteric modulation of the 5-HT~3~A receptor through chemical modification of engineered cysteines in the vestibule site.\
(**a**) Example traces of agonist-evoked channel responses of the L151C 5-HT~3A~R mutant before and after modification with MTSEA-biotin show potentiation after cysteine modification. (**b**) Location of L151C and other engineered cysteine mutants in this study, shown in ball and stick representation. (**c**) Concentration-activation curves before and after modification with MTSEA-biotin are a Hill curve fit for the recordings shown in (**a**) as well as additional data for T112C (**d**) and K149C. (**c--e**) Each of these three mutants reveal a leftward shift of the curve upon cysteine modification, consistent with a positive allosteric effect. In the case of L151C, this effect is combined with a large increase of the maximal current response.\
Figure 4---source data 1.Electrophysiological recordings of 5-HT~3~R mutants before and after treatment with MTSEA-biotin.](elife-51511-fig4){#fig4}

Representative current traces of channel responses to increasing concentrations of serotonin (5-HT) are shown in [Figure 4a](#fig4){ref-type="fig"} for the L151C mutant before and after modification with MTSEA-biotin. The channel responses are drastically increased after cysteine modification, which is caused by a more than 10-fold increase of the maximal current response (I~max~) of the concentration-activation curve after MTSEA-biotin modification as well as a shift of the EC~50~-value to lower concentrations ([Figure 4a,c](#fig4){ref-type="fig"}) (pEC~50~: 4.01 ± 0.03, n = 5 (EC~50~: 98 μM) versus pEC~50~: 4.96 ± 0.04, n = 5 (EC~50~: 11 μM)), indicating a strong PAM-effect at this position (p\<0.0001, mean values ± SEM). The L151C mutation alone causes a \~50 fold increase of the EC~50~-value compared to wild type (EC~50~98 μM versus 1.8 μM), suggesting that this mutation impacts function, possibly because L151 contributes to a hydrophobic patch in the center of the subunit (it is \<4 Å from I100 and L131), and this, or the mutation itself, could affect the adjacent Cys-loop and loop B. Modification of this residue with MTSEA-biotin appears to change the EC~50~ (11 μM) back toward wild-type value (1.8 μM). Mutants T112C and K149C also showed a lesser but significant decrease of the EC~50~-value after MTSEA-biotin, namely 6.7 μM (pEC~50~: 5.17 ± 0.02, n = 4) versus 2.9 μM (pEC~50~: 5.53 ± 0.02, n = 4) for T112C ([Figure 3d](#fig3){ref-type="fig"}) (p\<0.0001) and 6.2 μM (pEC~50~: 5.21 ± 0.05, n = 7) versus 2.1 μM (pEC~50~: 5.69 ± 0.11, n = 7) for K149C ([Figure 3e](#fig3){ref-type="fig"}) (p=0.005). Although neither of these mutants displayed an increase of I~max~ as in the L151C mutant, the leftward shift of the concentration-activation curve is also consistent with a PAM-effect at these positions. No significant differences were observed for current responses before and after MTSEA-biotin for Y86C, F125C and N147C or the negative control, P111C (see [Supplementary file 3](#supp3){ref-type="supplementary-material"}), suggesting modification of these residues does not place the MTSEA-biotin in an appropriate position to act as a modulator, although it is also possible it did not react here. Together, these results demonstrate that general perturbation of this area via a drug binding or a mutation can alter receptor activation and that allosteric modulation via the vestibule binding site is functionally conserved between ELIC and 5-HT~3A~ receptors. The evolutionary distance between these receptors, combined with previous work, suggests that this mechanism of modulation possibly also extends to other pLGIC members. In support of this hypothesis the functional importance of the vestibule site in channel modulation is now emerging from a wide range of different structural studies on prokaryote channels, demonstrating ELIC modulation by flurazepam ([@bib58]) or nanobodies (this study), 4-bromocinnamate modulation of the prokaryote homolog sTeLIC ([@bib25]), and acetate binding in GLIC ([@bib16]). Additionally, the vestibule site has been identified as the site of modulation in different eukaryote channels using various approaches, including 5-HT~3A~R modulation by cysteine-scanning mutagenesis (this study), α7 nAChR modulation using a fragment-based screening approach ([@bib60]; [@bib12]), and Zn^2+^-mediated inhibition of the α1 GlyR ([@bib40]).

Conclusion {#s2-5}
----------

In conclusion, we demonstrate here that functionally active nanobodies can be developed for the ligand-gated ion channel ELIC. Functional characterization demonstrates that nanobodies can act as positive or negative allosteric modulators on this channel. Previous structural studies on the mouse 5-HT~3~ receptor have also identified a nanobody with an inhibitory mode of action ([@bib21]), while a nanobody active as a positive allosteric modulator was recently developed for the human α1β3γ2 GABA~A~ receptor ([@bib42]). These results indicate that functionally active nanobodies can be developed for different prokaryote and eukaryote ligand-gated ion channels and that they are useful tools for structural studies.

Crystal structures reveal that ELIC nanobodies can interact via distinct epitopes, including accessible parts of allosteric binding sites previously discovered in the extracellular ligand-binding domain and bound by small molecules. One potentially attractive site for further development of allosteric modulators is the vestibule site, which can be targeted not only with nanobodies or small molecules in ELIC, but also by chemical modification of engineered cysteines as demonstrated in the human 5-HT~3A~ receptor. The vestibule site offers opportunities to further develop both positive and negative modulators, as well as to exploit subtype-specific access to certain receptors. These results pave the way for the future development of novel therapeutics that can modulate channel activity in pLGIC-related disorders. An attractive path would be to expand the currently available repertoire of therapeutics with pharmacologically active nanobodies against human pLGICs.

Materials and methods {#s3}
=====================

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\        Designation                                          Source or reference                             Identifiers                                                    Additional\
  or resource                                                                                                                                                                                        information
  ------------------------------ ---------------------------------------------------- ----------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene                           *Erwinia* ligand-gated ion channel (ELIC)            Synthetic gene from Genscript                   UniProt\                                                       
                                                                                                                                      P0C7B7                                                         

  Gene                           Human 5-hydroxytryptamine receptor 3A (5-HT~3A~ R)   John Peters laboratory ([@bib4])                GenBank NM_000869                                              

  Cell line                      C43 *E. coli* strain                                 Lucigen                                         \#60446                                                        

  Cell line                      WK6 *E. coli* strain                                 [@bib66]\                                                                                                      

  Cell line                      TG1 *E. coli* strain                                 Lucigen                                         \#60502                                                        

  Antibody                       PAM-Nb                                                                                                                                                              Nanobody obtained by immunizing an adult *llama glama* with recombinant ELIC protein. PAM-Nb was used at 1--30 μM concentration in electrophysiology experiments. In protein crystals the PAM-Nb concentration is \> 1 mM.

  Antibody                       NAM-Nb                                                                                                                                                              Nanobody obtained by immunizing an adult *llama glama* with recombinant ELIC protein. NAM-Nb was used at 0.03--3 μM concentration in electrophysiology experiments. In protein crystals the NAM-Nb concentration is \> 1 mM.

  Recombinant DNA reagent        pGEM-HE                                              [@bib36]\                                                                                                      

  Recombinant DNA reagent        pMESy4                                                                                               GenBank KF415192                                               

  Sequence-based reagent         P111C oligonucleotide forward and reverse                                                                                                                           5'-caccaagttgtccatcTGcacggacagcatctgg-3'\
                                                                                                                                                                                                     5'-ccagatgctgtccgtgCAgatggacaacttggtg- 3'

  Sequence-based reagent         T112C oligonucleotide forward and reverse                                                                                                                           5'-caagttgtccatccccTGCgacagcatctgggtcc-3'\
                                                                                                                                                                                                     5'-ggacccagatgctgtcGCAggggatggacaacttg-3'

  Sequence-based reagent         N147C oligonucleotide forward and reverse                                                                                                                           5'-caaggcgaagttcagTGctacaagccccttcagg-3'\
                                                                                                                                                                                                     5'-cctgaaggggcttgtagCActgaacttcgccttg-3'

  Sequence-based reagent         K149C oligonucleotide forward and reverse                                                                                                                           5'-ggcgaagttcagaactacTGCccccttcaggtggtga-3'\
                                                                                                                                                                                                     5'- tcaccacctgaaggggGCAgtagttctgaacttcgcc-3'

  Sequence-based reagent         L151C oligonucleotide forward and reverse                                                                                                                           5'- gttcagaactacaagcccTGtcaggtggtgactgc-3'\
                                                                                                                                                                                                     5'-gcagtcaccacctgaCAgggcttgtagttctgaac-3'

  Sequence-based reagent         Y86C oligonucleotide forward and reverse                                                                                                                            5'- ctggtaccggcagtGctggactgatgag-3'\
                                                                                                                                                                                                     5'-ctcatcagtccagCactgccggtaccag-3'

  Sequence-based reagent         F125C oligonucleotide forward and reverse                                                                                                                           5'-ggacattctcatcaatgagtGcgtggatgtggg-3'\
                                                                                                                                                                                                     5'-cccacatccacgCactcattgatgagaatgtcc-3'

  Sequence-based reagent         Primer for nanobody library generation\              [@bib49]\                                                                                                      5′-GTCCTGGCTGCTCTTCTACAAGG-3′
                                 CALL001                                                                                                                                                             

  Sequence-based reagent         Primer for nanobody library generation\              [@bib49]\                                                                                                      5′-GGT ACGTGCTGTTGAACTGTTCC-3′
                                 CALL002                                                                                                                                                             

  Sequence-based reagent         Primer for nanobody library generation\              [@bib49]\                                                                                                      5′-GATGTGCAGCTGCAG GAGTCTGGRGGAGG-3′(PstI)
                                 VHH-Back                                                                                                                                                            

  Sequence-based reagent         Primer for nanobody library generation\              [@bib49]\                                                                                                      5′-CTAGTGCGGCCGCTGG AGACGGTGACCTGGGT-3′(Eco91I)
                                 VHH-For                                                                                                                                                             

  Sequence-based reagent         Primer for nanobody library analysis\                [@bib49]\                                                                                                      5′-TTATGCTTCCGGCTC GTATG-3′
                                 MP57                                                                                                                                                                

  Peptide, recombinant protein   Primer for nanobody library analysis\                [@bib49]\                                                                                                      5′-CCACAGACAGCCCTCATAG-3′
                                 GIII                                                                                                                                                                

  Commercial assay or kit        mMessage mMachine T7 Transcription kit               ThermoFisher Scientific                         \#AM1344                                                       

  Commercial assay or kit        Ni Sepharose 6 Fast Flow resin                       GE Healthcare                                   \#17531802                                                     

  Commercial assay or kit        Superdex 75 10/300 GL column                         GE Healthcare                                   \# 17-5174-01                                                  

  Commercial assay or kit        Superdex 200 Increase 10/300 GL                      GE Healthcare                                   \# 28990944                                                    

  Commercial assay or kit        QuikChange Site-Directed Mutagenesis Kit             Agilent                                         \# 200518                                                      

  Chemical compound, drug        5-HT creatinine sulphate                             Sigma-Aldrich                                   \#S2805                                                        

  Chemical compound, drug        MTSEA-biotin                                         Biotium                                         \#90064                                                        

  Chemical compound, drug        GABA                                                 Sigma-Aldrich                                   \#A2129                                                        

  Chemical compound, drug        *E. coli* total lipid extract                        Avanti Polar Lipids                             \#100500P                                                      

  Chemical compound, drug        Anagrade n-undecyl-β-D-maltoside (UDM)               Anatrace                                        \#U300                                                         

  Software, algorithm            GraphPad Prism Software v4.03                                                                        RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)   

  Software, algorithm            CCP4                                                 [@bib65]\                                                                                                      

  Software, algorithm            STARANISO                                            [@bib61] <http://staraniso.globalphasing.org>                                                                  

  Software, algorithm            XDS                                                  [@bib29]\                                                                                                      

  Software, algorithm            Coot                                                 [@bib15]\                                                                                                      

  Software, algorithm            Buster                                               [@bib57]\                                                                                                      

  Software, algorithm            PDB-REDO                                             [@bib27]\                                                                                                      

  Software, algorithm            MolProbity                                           [@bib10]\                                                                                                      

  Software, algorithm            PyMOL v2.3.0                                         Schrödinger                                     RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)   

  Software, algorithm            HOLE                                                 [@bib56]\                                                                                                      

  Software, algorithm            CAVER                                                [@bib28]\                                                                                                      

  Software, algorithm            PHENIX                                               [@bib1]\                                                                                                       

  Software, algorithm            HiClamp                                              Multi Channel Systems                                                                                          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Production of nanobodies against ELIC {#s3-1}
-------------------------------------

A llama was immunized with 2 mg in total of purified wild type ELIC protein over a period of 6 weeks using a previously established protocol ([@bib49]). Briefly, from the anti-coagulated blood of the immunized llama, lymphocytes were used to prepare cDNA. This cDNA served as a template to amplify the open reading frames coding for the variable domains of the heavy-chain only antibodies, also called nanobodies. The PCR fragments were ligated into the pMESy4 phage display vector and transformed in *E. coli* TG1 cells. A nanobody library of 1.1 × 10^8^ transformants was obtained. For the discovery of ELIC-specific nanobodies, wild-type ELIC was solid phase coated directly on plates and phages were recovered by limited trypsinization. After two rounds of selection, periplasmic extracts were made and subjected to ELISA screens, seven different families were confirmed by sequence analysis. All clones were produced and purified as previously described ([@bib49]).

Nanobody expression and purification {#s3-2}
------------------------------------

A series of nanobodies were individually expressed in the periplasm of *E. coli* strain WK6, which was grown in TB media supplemented with 0.1 mg/ml carbenicillin, 0.1% glucose and 2 mM MgCl~2~ to an absorbance A~600~ \~0.7 at 37°C. The culture was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated in an orbital shaker overnight at 28°C. Cells were harvested by centrifugation, resuspended in TES buffer (200 mM TRIS, pH 8.0; 0.5 mM EDTA; 500 mM sucrose supplemented with 40 mM imidazole) and incubated for 1 hr. To this fraction four times diluted TES buffer was added and incubated for 1 hr. This fraction was cleared by centrifugation at 10,000 g. The supernatant was incubated with Ni Sepharose 6 Fast Flow resin (GE Healthcare) and incubated for 1 hr at room temperature. The beads were washed with buffer containing 20 mM TRIS pH 8.0, 300 mM NaCl and 40 mM imidazole. Protein was eluted with the same buffer supplemented with 300 mM imidazole. The eluted protein was concentrated to less than 1 ml on a 3 kDa cut-off Vivaspin concentrating column (Sartorius) and further purified on a Superdex 75 10/300 GL column (GE Healthcare) equilibrated with 10 mM Na-phosphate (pH 8.0) and 150 mM NaCl. Peak fractions corresponding to nanobody were pooled and spin-concentrated to \~50 mg/ml.

Automated voltage-clamp recordings of ELIC {#s3-3}
------------------------------------------

For expression of ELIC in *Xenopus* oocytes, we used the pGEM-HE expression plasmid ([@bib36]) containing the signal sequence of the human α7 nAChR followed by the mature ELIC sequence, as previously described ([@bib58]). After plasmid linearization with *Nhe*I, capped mRNA was transcribed in vitro using the mMESSAGE mMACHINE T7 transcription kit (ThermoFisher). 2 ng of mRNA per oocyte was injected into the cytosol of stage V and VI oocytes using the Roboinject automated injection system (Multi Channel Systems). Oocyte preparations and injections were done using standard procedures ([@bib31]). Injected oocytes were incubated in ND96-solution containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~, 2 mM MgCl~2~ and 5 mM HEPES, pH 7.4, supplemented with 50 mg/L gentamicin sulfate. One to five days after injection, electrophysiological recordings were performed at room temperature by automated two-electrode voltage clamp with the HiClamp apparatus (Multi Channel Systems). Cells were superfused with standard OR2 solution containing 82.5 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl~2~, 1 mM MgCl~2~, 5 mg/L BSA and 5 mM HEPES buffered at pH 7.4. Cells were held at a fixed potential of −80 mV throughout the experiment. Agonist-evoked current responses were obtained by perfusing oocytes with a range of GABA concentrations in OR2 solution. Different nanobodies diluted into OR2 solution were tested at a range of concentrations by pre-incubation with nanobody alone and followed by a co-application of nanobody with 5 mM GABA. Data acquired with the HiClamp were analyzed using the manufacturer's software (Multi Channel Systems). Concentration-activation curves were fitted with the empirical Hill equation as previously described ([@bib58]). Data are presented as the mean ± standard error of the mean (SEM) with the raw data points overlaid as a dot plot in the relevant figures.

ELIC purification and crystallization of ELIC-nanobody complexes {#s3-4}
----------------------------------------------------------------

Purified ELIC protein was produced as previously described, but with minor modifications ([@bib58]). In brief, the ELIC expression plasmid was transformed into the C43 *E. coli* strain and cells were grown in LB medium. Protein expression was induced with 200 μM isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated in an orbital shaker at 20°C overnight. After cell lysis, membranes were collected by ultracentrifugation at 125,000 x g and solubilized with 2% (w/v) anagrade n-undecyl-β-D-maltoside (UDM, Anatrace) at 4°C overnight. The cleared supernatant containing the solubilized MBP-ELIC fusion protein was purified by affinity chromatography on amylose resin (New England Biolabs). Column-bound ELIC was cleaved off by 3CV protease in the presence of 1 mM EDTA + 1 mM DTT at 4°C overnight. A final purification step was carried out on a Superdex 200 Increase 10/300 GL column (GE Healthcare) equilibrated with buffer containing 10 mM Na-phosphate pH 8.0, 150 mM NaCl, and 0.15% n-undecyl-β-D-maltoside (UDM, Anatrace). Peak fractions containing pentameric ELIC were pooled, concentrated to \~10 mg/mL and relipidated with 0.5 mg/mL *E. coli* lipids (Avanti Polar Lipids). Nanobodies were added at a 20% molar excess calculated for monomers and incubated at room temperature 2 hr prior to setting up crystallization screens with a Mosquito liquid handling robot (TTP Labtech). Crystals for the ELIC complex with PAM-Nb grew at room temperature in the presence of 0.1 M GABA, 0.2 M Ca(OAc)~2~, 0.1 M MES buffer pH 6.5% and 10% PEG8000. Crystals for the ELIC complex with NAM-Nb grew at room temperature in the presence of 0.1 M Na~2~SO~4~, 0.1 M bis-trispropane pH 8.5% and 10% PEG3350. Crystals were harvested after adding cryo-protectant containing mother liquor gradually supplemented with up to 25% glycerol in 5% increments. Crystals were then plunged into liquid nitrogen and stored in a dewar for transport to the synchrotron.

Structure determination of ELIC-nanobody complexes {#s3-5}
--------------------------------------------------

Diffraction data for the ELIC+PAM-Nb structure were collected at the PROXIMA 1 beamline of the SOLEIL synchrotron (Gif-sur-Yvette, France). Diffraction data for the ELIC+NAM-Nb structure were collected at the X06A beamline of the Swiss Light Source (Villigen, Switzerland). Both structures were solved by molecular replacement with Phaser in the CCP4 suite ([@bib65]) using the published structures for the ELIC pentamer (pdb 2vl0) and a GPCR nanobody (pdb 3p0g) as search templates. For the ELIC+PAM-Nb structure, the asymmetric unit contains one ELIC pentamer with five nanobodies bound (one to each subunit). For the ELIC+NAM-Nb structure, the asymmetric unit contains two ELIC pentamers with one nanobody bound to each pentamer. The electron density for one of these nanobody molecules is not well defined, suggesting partial occupancy at this pentamer, and therefore the atom occupancies for this nanobody were manually set to 40% during structure refinement. The data set for the ELIC+NAM-Nb was anisotropic with data extending to \~3.15 Å in the best direction and \~3.5 Å in the worst. To correct for anisotropy the unmerged reflections from XDS ([@bib29]) were uploaded to the STARANISO server ([@bib61]) and automatically processed using CC1/2 \> 30 and I/σ \>2 as resolution cut-off criteria. The merged and scaled data set from this procedure extends to a resolution of 3.25 Å and the statistics produced by the STARANSIO server are shown in the crystallographic table ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). Structures were improved by iterative rounds of manual rebuilding in Coot ([@bib15]) and automated refinement in Buster ([@bib57]) or Refmac ([@bib65]). Structure validation was carried out in PDB-REDO ([@bib27]) and MolProbity ([@bib10]). Figures were prepared with PyMOL (Schrödinger) and UCSF-Chimera ([@bib50]). Pore radius profiles were made using HOLE ([@bib56]) and CAVER ([@bib28]). Simulated annealing omit maps were calculated in PHENIX ([@bib1]) and are shown for the nanobody-ELIC interaction region ([Figure 1---figure supplements 2](#fig1s2){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}).

Cysteine-scanning mutagenesis and voltage-clamp recordings of 5-HT~3A~R {#s3-6}
-----------------------------------------------------------------------

Stage V-VI *Xenopus* oocytes were purchased from Ecocyte (Germany) and stored in ND-96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2,~1 mM MgCl~2~, 5 mM HEPES, pH 7.5) containing 2.5 mM sodium pyruvate, 50 mM gentamicin and 0.7 mM theophylline. cDNA encoding human 5-HT~3A~R was cloned into the pGEM-HE expression plasmid ([@bib36]). Mutants were engineered using the QuikChange mutagenesis kit (Agilent) and confirmed by sequencing. cRNA was in vitro transcribed from linearized pGEM-HE cDNA template using the mMessage mMachine T7 Transcription kit (ThermoFisher). Oocytes were injected with 50 nl of \~400 ng/μl cRNA, and currents were recorded 18--48 hr post-injection. 5-HT~3A~R current recordings were obtained using a Roboocyte voltage-clamp system (Multi Channel systems) at a constant voltage clamp of −60 mV. Oocytes were perfused with ND-96 with no added calcium, and 5-HT (creatinine sulphate complex, Sigma) was diluted in this media. Oocytes were tested at 10 μM 5-HT before obtaining concentration-response curves. MTSEA-biotin (Biotium) was diluted immediately prior to application into calcium-free ND-96 solution at a concentration of 2 mM from a stock solution of 500 mM in DMSO. Analysis and curve fitting was performed using Prism v4.03 (GraphPad Software). Concentration-response data for each oocyte were normalized to the maximum current for that oocyte. Data are presented as the mean ± standard error of the mean (SEM) with the raw data points overlaid as a dot plot in the relevant figures.

Transparent reporting statements {#s3-7}
--------------------------------

All *Xenopus* electrophysiology experiments were repeated three to eight times. The number of 'n' is mentioned in the relevant sections of the main text. We define each separate oocyte recording as a biological repeat. No data were excluded, unless the oocyte gave no detectable current. All electrophysiology experiments were conducted on automated devices, either the HiClamp or the Roboocyte, so essentially there was no human bias in recording of these data. Data are presented as the mean ± standard error of the mean (SEM) with the raw data points overlaid as a dot plot. Statistical comparison between groups of data was performed using an unpaired two-tailed *t* test or an ANOVA followed by a Dunnetts multiple comparisons test as appropriate; the significance value p is mentioned in the relevant sections of the manuscript.

The X-ray diffraction data sets were collected from single crystals and typically the data set with the highest resolution was used for structural elucidation. Equivalent reflection data were recorded multiple times in agreement with the rotational symmetry of the crystal packing. The relevant data multiplicity value for each data set is mentioned in the crystallographic table ([Supplementary file 1](#supp1){ref-type="supplementary-material"}). All aspects of X-ray data collection, integration, scaling and merging were fully automated so human bias was excluded. No data were excluded.
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Atomic coordinates and structure factors have been deposited with the Protein Data Bank under accession numbers 6SSI for the ELIC+PAM-Nb structure and 6SSP for the ELIC+NAM-Nb structure. The raw X-ray diffraction images for both data sets have been deposited on Dryad under DOI <https://doi.org/10.5061/dryad.pv4097s>.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Using a combination of X-ray crystallography and targeted mutagenesis combined with functional assays, this manuscript identifies two nanobodies that allosterically modulate the bacterial pentameric ligand-gated ion channel (pLGIC), ELIC, and examines the structural mechanisms underlying their functional effects. One nanobody acts as a positive allosteric modulator (PAM) and the other a negative allosteric modulator (NAM). X-ray crystal structures reveal that the NAM-nanobody binds to a novel site in the upper extracellular domain vestibule of ELIC. The PAM-nanobody binding site overlaps with a previously-identified allosteric drug site in the related nicotinic acetylcholine receptor. Guided by the structures, the authors examine the vestibule binding site in the related serotonin type 3 receptor and show that perturbing this region (via covalent modification and/or mutation) alters channel activation suggesting the site might represent a new region to target for drug development. The data provide new information about mechanisms underlying allosteric modulation of pLGICs and will be of interest to many in the field.

**Decision letter after peer review:**

Thank you for submitting your article \"A functionally conserved mechanism of modulation via a vestibule site in pentameric ligand-gated ion channels\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Kenton Swartz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Alexander Sobolevsky (Reviewer \#1); Alexandru Radu Aricescu (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The major results and conclusions are:

1\) Identified two nanobodies that bind to ELIC: one that acts as a positive allosteric modulator (PAM) and the other as a negative allosteric modulator (NAM).

2\) Solved high-resolution structures of ELIC bound to PAM-nanobody and to NAM-nanobody.

3\) The NAM-nanobody binds to a novel site in the upper ECD vestibule of ELIC.

4\) Covalently linking a bulky reagent MTSE-biotin into a pocket in the vestibule region in the 5HT3R modulates serotonin-evoked currents suggesting the upper ECD vestibule might represent a new target for developing drugs.

The authors\' conclusions are supported by the experimental data. The manuscript is well written and offers new insights into a novel intra-vestibule binding site on pentameric ligand-gated ion channels (pLGICs).

Addressing the following essential revisions will strengthen the manuscript.

Essential Revisions:

1\) Revise title so it is less general and does not overstate manuscript\'s main conclusion. Abstract should be revised and describe specific experiments done and results of these experiments. Do not generalize results to all pLGICs.

2\) Previous work from Hassaine et al., 2014 (5HT3R) and Miller et al., 2018 (bioRxiv) have reported that nanobodies modulate pLGIC function -- please mention this point and add references.

3\) A modulatory drug vestibule site may not be a general feature of all pLGICs. For GABA-A receptors, vestibule is occupied by glycans and thus is not accessible. Authors need to be careful not to generalize the conclusions drawn from their work to all pLGIC members.

4\) Authors need a more thorough analysis/discussion of residues involved in positive versus negative modulation. Figure 2 needs to be revised and/or an additional supplementary figure should be included to highlight the residue side chains that interact with the nanobodies versus small ligands. Compare and contrast nanobody interaction residues with CU2017 and flurazepam contact residues. Providing dose-response curves in the presence of the nanobodies would provide additional mechanistic insight into their mode of action.

5\) Please include/discuss whether there any examples of allosteric modulators that bind in the vestibule of other members of the pLGIC superfamily e.g. nAChRs, GABARs, GlyRs, 5HT3Rs. Could pLGICs with omega-in and omega-out conformations also be modulated via the vestibule?

6\) Include data showing effects of MTSEA-biotin on wild-type ELIC (control). Provide rationale for using MTSEA-biotin as the modifying reagent. Summarize SCAM results for the tested cysteine mutant receptors in a table.

7\) NAM nanobody blocks vestibule but only 35% of the GABA evoked current can be blocked. Additional discussion is needed to support idea that current enters via fenestrations at subunit interfaces. Show on ELIC structure where this could take place along with assessments of ion sizes in relation to fenestration/tunnel dimensions. Alternative mechanisms are possible and should be discussed. Could NAM-NB binding restrict flexibility in the ECD, thereby reducing the efficacy of the orthosteric agonist? Is it possible that the NAM-Nb-bound vestibule is occluded in the apo/desensitized states but not in an open state, due to an agonist-induced conformational change?

8\) The authors\' need to elaborate more about omega loop and how they envision this region of the protein regulating channel activation and drug modulation. Are conformations of the omega loop different in GluCl apo, open, desensitized conformations, GLIC apo, open, desensitized structures, and in different GABA-A receptor conformations. Do they imagine this loop intrinsically flexible? Do you think only omega-open channels are drug targets? Previous studies on nACHR (Chakrapani, Bailey and Auerbach, 2003) and GABA-A receptors (Hanek, Lester and Dougherty, 2010; Ventatachalan and Czajkowski, 2012) have mutated this region and should be discussed.

9\) Flurazepam is a \'classic\' benzodiazepine targeting an extracellular binding site between α- and γ-subunits of GABA-A receptors, quite far from the (occluded) Ω-out vestibular site. It will be useful for the general reader, if you mention that flurazepam has more than one binding site in the pLGIC family. It should be clearly stated that flurazepam site in ELIC is not the site that corresponds to its action on the eukaryotic GABAR.

10\) L151C modification by MTSEA-biotin has large functional effects. Can the authors comment on why? The cysteine substitution of L151 alone has large effects on function. Please discuss.

11\) Figures 1 and 4 -- please include the number of experiments performed for each of the dose response curves. Data are mean +/- SEM?

12\) NAM nanobody site in ELIC does not overlap with previously identified flurazepam site. NAM nanobody site sits above the cavity that binds flurazepam. Please comment on and discuss.

13\) Previous studies have shown that targeted modification of introduced cysteine residues by sulfhydryl reactive reagents throughout the ECD and TMD of many different pLGICs alter channel activation and/or drug modulation. It is unlikely that all of these sites are targets for drug development. The SCAM experiments are interesting and demonstrate that structural perturbations at these residues effect receptor activation but authors need to be careful about interpreting the data as evidence for a conserved allosteric binding site in the vestibule.

10.7554/eLife.51511.sa2

Author response

> Essential Revisions:
>
> 1\) Revise title so it is less general and does not overstate manuscript\'s main conclusion. Abstract should be revised and describe specific experiments done and results of these experiments. Do not generalize results to all pLGICs.

We have revised the title and Abstract as requested.

> 2\) Previous work from Hassaine et al., 2014 (5HT3R) and Miller et al., 2018 (bioRxiv) have reported that nanobodies modulate pLGIC function -- please mention this point and add references.

These references are now cited and discussed in the subsection "Conclusion".

> 3\) A modulatory drug vestibule site may not be a general feature of all pLGICs. For GABA-A receptors, vestibule is occupied by glycans and thus is not accessible. Authors need to be careful not to generalize the conclusions drawn from their work to all pLGIC members.

We agree that modulation via the vestibule site may not be a general feature of pLGICs and have been more cautious in this revised version, where we have also mentioned N-linked glycan access restriction of the vestibule in GABA~A~ receptors (subsection "Subtype-dependent vestibule site access in different prokaryote and eukaryote receptors", last paragraph).

> 4\) Authors need a more thorough analysis/discussion of residues involved in positive versus negative modulation. Figure 2 needs to be revised and/or an additional supplementary figure should be included to highlight the residue side chains that interact with the nanobodies versus small ligands. Compare and contrast nanobody interaction residues with CU2017 and flurazepam contact residues. Providing dose-response curves in the presence of the nanobodies would provide additional mechanistic insight into their mode of action.

These are good suggestions. We have now analyzed residues involved in PAM-Nb and NAM-Nb interactions in more detail and compared them to CU2017 (NAM) and flurazepam (PAM) interactions, respectively. This is discussed in the third paragraph of the subsection "Crystal structures of ELIC in complex with a PAM- or NAM-type nanobody", and new Figure 2---figure supplement 1-2.

We have also determined GABA concentration-activation curves in the presence of nanobodies as suggested, and indeed this has revealed further mechanistic insight consistent with their mode of action as allosteric modulators. This is discussed in the last paragraph of the subsection "Identification of nanobodies active as allosteric modulators on ELIC", and new Figure 1---figure supplement 1.

> 5\) Please include/discuss whether there any examples of allosteric modulators that bind in the vestibule of other members of the pLGIC superfamily e.g. nAChRs, GABARs, GlyRs, 5HT3Rs. Could pLGICs with omega-in and omega-out conformations also be modulated via the vestibule?

We now describe several known examples of vestibule site modulators in different members of the pLGIC superfamily in the last paragraph of the subsection "Cysteine-scanning mutagenesis in the vestibule site of the human 5-HT3A receptor".

Regarding the modulation of Ω-in and Ω-out conformations, our structural analysis shows that vestibule access for these is restricted. It is perhaps possible (as we discuss in the revised manuscript) that ligand-induced conformational changes of the Ω-loop could occur, permitting vestibule site access, but in the absence of any evidence this is too speculative to consider in any detail.

> 6\) Include data showing effects of MTSEA-biotin on wild-type ELIC (control). Provide rationale for using MTSEA-biotin as the modifying reagent. Summarize SCAM results for the tested cysteine mutant receptors in a table.

We assume this remark relates to the 5-HT~3~ receptor, not to ELIC. The data are now summarized in a new Supplementary file 3 along with data from wild type 5-HT~3~R (where the lack of effect of MTSEA-biotin was previously demonstrated in Thompson et al., 2011). We also provide a rationale for using MTSEA-biotin in the first paragraph of the subsection "Cysteine-scanning mutagenesis in the vestibule site of the human 5-HT3A receptor".

> 7\) NAM nanobody blocks vestibule but only 35% of the GABA evoked current can be blocked. Additional discussion is needed to support idea that current enters via fenestrations at subunit interfaces. Show on ELIC structure where this could take place along with assessments of ion sizes in relation to fenestration/tunnel dimensions. Alternative mechanisms are possible and should be discussed. Could NAM-NB binding restrict flexibility in the ECD, thereby reducing the efficacy of the orthosteric agonist? Is it possible that the NAM-Nb-bound vestibule is occluded in the apo/desensitized states but not in an open state, due to an agonist-induced conformational change?

We analyzed ELIC structures in apo as well as nanobody-bound structures and found lateral fenestrations at the same location as in the β3 GABA~A~ receptor structure (PDB 4COF), although slightly smaller in radius. This provides additional support for an alternate ion pathway in the NAM-Nb bound ELIC state. This analysis was conducted using the program CAVER, which also revealed a partially-blocked ion conduction pathway along the extracellular vestibule entrance. This result was also confirmed using the program HOLE and could provide an additional explanation for the partial reduction of the GABA-evoked current in the presence of NAM-Nb. Finally, we also agree with the reviewer that the NAM-Nb could restrict flexibility in the ECD, thereby limiting a gating transition to an open/active conformation. This is now discussed in the last paragraph of the subsection "Crystal structures of ELIC in complex with a PAM- or NAM-type nanobody".

We have updated the pore radius profiles throughout the study with the results from HOLE and CAVER, as the program CHAP appears to produce deviating results for the vestibule entrance (see [Author response image 1](#respfig1){ref-type="fig"}).

![](elife-51511-resp-fig1){#respfig1}

> 8\) The authors\' need to elaborate more about omega loop and how they envision this region of the protein regulating channel activation and drug modulation. Are conformations of the omega loop different in GluCl apo, open, desensitized conformations, GLIC apo, open, desensitized structures, and in different GABA-A receptor conformations. Do they imagine this loop intrinsically flexible? Do you think only omega-open channels are drug targets? Previous studies on nACHR (Chakrapani, Bailey and Auerbach, 2003) and GABA-A receptors (Hanek, Lester and Dougherty, 2010; Ventatachalan and Czajkowski, 2012) have mutated this region and should be discussed.

We have elaborated on this in the revised manuscript. A comprehensive analysis of all pLGIC structures available to date, including \>100 GLIC structures, revealed no clear correlation between the Ω-loop conformation and apo, open, desensitized structures in GluCl or GLIC, or any other pLGICs. Analysis of the average B-factor per residue, which is used as an indicator of vibrational movement, did reveal that in certain structures the Ω-loop has enhanced B-factors relative to other parts of the structure. Some of the most striking examples are the Ω-in loop of the a3 subunit in the a3b4 nAChR (PDB code 6PV7, desensitized state) (Gharpure et al., 2019), the Ω-out loop in POPC-bound GluCl (PDB code 4TNW, lipid-modulated state) (Althoff et al., 2014) and the Ω-open loop in GLIC T25'A (PDB code 4LMJ, liganded closed state) (Gonzalez-Gutierrez et al., 2013). These examples also represent possible intermediate or end states of the gating cycle, suggesting that the Ω-loop could show enhanced movement during the gating reaction. This is consistent with the very relevant studies mentioned by the reviewers, which are now cited and discussed (subsection "Subtype-dependent vestibule site access in different prokaryote and eukaryote receptors").

> 9\) Flurazepam is a \'classic\' benzodiazepine targeting an extracellular binding site between α- and γ-subunits of GABA-A receptors, quite far from the (occluded) Ω-out vestibular site. It will be useful for the general reader, if you mention that flurazepam has more than one binding site in the pLGIC family. It should be clearly stated that flurazepam site in ELIC is not the site that corresponds to its action on the eukaryotic GABAR.

We now state explicitly that flurazepam has multiple binding sites and that the vestibule site in ELIC does not correspond to the high affinity binding benzodiazepine binding site in human GABA~A~Rs. See the third paragraph of the subsection "Crystal structures of ELIC in complex with a PAM- or NAM-type nanobody".

> 10\) L151C modification by MTSEA-biotin has large functional effects. Can the authors comment on why? The cysteine substitution of L151 alone has large effects on function. Please discuss.

This is indeed interesting as the L151C mutation alone significantly increases the EC~50~-value compared to wild type (EC~50~ 98 µM versus 1.8 µM) suggesting that this mutation impacts function. In the revised manuscript we suggest it might be because L151 contributes to a hydrophobic patch in the center of the subunit (it is \< 4 Å from I100 and L131) and this -- or the mutation itself -- could affect the adjacent Cys-loop and loop B. This is discussed in the last paragraph of the subsection "Cysteine-scanning mutagenesis in the vestibule site of the human 5-HT3A receptor".

> 11\) Figures 1 and 4 -- please include the number of experiments performed for each of the dose response curves. Data are mean +/- SEM?

The number of experiments is now mentioned in the text as well as the summarizing SCAM table (new Supplementary file 3). Data are presented as the mean ± standard error of the mean (SEM) with the raw data points overlaid as a dot plot in the relevant figures. We now mention this specifically in the last paragraphs of the subsections "Identification of nanobodies active as allosteric modulators on ELIC" (Figure 1), "Cysteine-scanning mutagenesis in the vestibule site of the human 5-HT3A receptor" (Figure 4), the Materials and methods section, and in the "Transparent Reporting Form".

> 12\) NAM nanobody site in ELIC does not overlap with previously identified flurazepam site. NAM nanobody site sits above the cavity that binds flurazepam. Please comment on and discuss.

The NAM-Nb interaction site is the a'1-helix in ELIC (N60-N69), which forms the top of the vestibule binding site. The flurazepam site and NAM-Nb site are adjacent to each other, see new Figure 2---figure supplement 2. This is discussed in the third paragraph of the subsection "Crystal structures of ELIC in complex with a PAM- or NAM-type nanobody".

> 13\) Previous studies have shown that targeted modification of introduced cysteine residues by sulfhydryl reactive reagents throughout the ECD and TMD of many different pLGICs alter channel activation and/or drug modulation. It is unlikely that all of these sites are targets for drug development. The SCAM experiments are interesting and demonstrate that structural perturbations at these residues effect receptor activation but authors need to be careful about interpreting the data as evidence for a conserved allosteric binding site in the vestibule.

The reviewer is correct that SCAM experiments should be interpreted with caution, but at the structural level the 5-HT~3~ receptor has an accessible vestibule site that very closely resembles ELIC. At the functional level, the mutagenesis and SCAM experiments also closely mimic the potentiation of ELIC by flurazepam. Combined, these data suggest that receptors with an accessible vestibule such as the 5-HT~3~ receptor could be targets for drug development.
